Table 2.
Initial medications after HTX.
| Parameter | All (n = 625) |
No Lung Cancer after HTX (n = 584) |
Lung Cancer after HTX (n = 41) |
Difference | 95% CI | p-Value |
|---|---|---|---|---|---|---|
| Immunosuppressive drug therapy | ||||||
| Cyclosporine A, n (%) | 347 (55.5%) | 319 (54.6%) | 28 (68.3%) | 13.7% | −1.1–28.5% | 0.09 |
| Tacrolimus, n (%) | 278 (44.5%) | 265 (45.4%) | 13 (31.7%) | 13.7% | −1.1–28.5% | 0.09 |
| Azathioprine, n (%) | 267 (42.7%) | 244 (41.8%) | 23 (56.1%) | 14.3% | −1.4–30.0% | 0.07 |
| Mycophenolate mofetil, n (%) | 358 (57.3%) | 340 (58.2%) | 18 (43.9%) | 14.3% | −1.4–30.0% | 0.07 |
| Steroids, n (%) | 625 (100.0%) | 584 (100.0%) | 41 (100.0%) | 0.0% | n. a. | n. a. |
| Concomitant medications | ||||||
| ASA, n (%) | 64 (10.2%) | 58 (9.9%) | 6 (14.6%) | 4.7% | −6.4–15.8% | 0.34 |
| Beta blocker, n (%) | 113 (18.1%) | 107 (18.3%) | 6 (14.6%) | 3.7% | −7.6–15.0% | 0.55 |
| Ivabradine, n (%) | 54 (8.6%) | 52 (8.9%) | 2 (4.9%) | 4.0% | −3.0–11.0% | 0.38 |
| Calcium channel blocker, n (%) | 165 (26.4%) | 150 (25.7%) | 15 (36.6%) | 10.9% | −4.3–26.1% | 0.13 |
| ACE inhibitor/ARB, n (%) | 276 (44.2%) | 253 (43.3%) | 23 (56.1%) | 12.8% | −2.9–28.5% | 0.11 |
| Diuretic, n (%) | 625 (100.0%) | 584 (100.0%) | 41 (100.0%) | 0.0% | n. a. | n. a. |
| Statin, n (%) | 241 (38.6%) | 222 (38.0%) | 19 (46.3%) | 8.3% | −7.5–24.1% | 0.29 |
| Gastric protection †, n (%) | 625 (100.0%) | 584 (100.0%) | 41 (100.0%) | 0.0% | n. a. | n. a. |
Abbreviations: ASA = acetylsalicylic acid; ACE inhibitor = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; CI = confidence interval; HTX = heart transplantation; n = number; n. a. = not applicable; † = gastric protection defined as proton pump inhibitor (PPI) or histamine receptor (H2) blocker.